Poland
· Delayed Price · Currency is PLN Read-Gene Statistics
Total Valuation
Read-Gene has a market cap or net worth of PLN 56.47 million. The enterprise value is 58.32 million.
| Market Cap | 56.47M |
| Enterprise Value | 58.32M |
Important Dates
The next estimated earnings date is Monday, February 10, 2025.
| Earnings Date | Feb 10, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Read-Gene has 11.79 million shares outstanding.
| Current Share Class | n/a |
| Shares Outstanding | 11.79M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 7.16% |
| Owned by Institutions (%) | n/a |
| Float | 1.27M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.46 |
| PB Ratio | 15.67 |
| P/TBV Ratio | 15.69 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -128.05 |
| EV / Sales | 4.60 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -245.39 |
Financial Position
The company has a current ratio of 7.88, with a Debt / Equity ratio of 2.09.
| Current Ratio | 7.88 |
| Quick Ratio | 7.85 |
| Debt / Equity | 2.09 |
| Debt / EBITDA | 53.81 |
| Debt / FCF | -31.63 |
| Interest Coverage | -0.96 |
Financial Efficiency
Return on equity (ROE) is -12.09% and return on invested capital (ROIC) is -2.38%.
| Return on Equity (ROE) | -12.09% |
| Return on Assets (ROA) | -1.78% |
| Return on Invested Capital (ROIC) | -2.38% |
| Return on Capital Employed (ROCE) | -3.02% |
| Revenue Per Employee | 575,933 |
| Profits Per Employee | -20,702 |
| Employee Count | 29 |
| Asset Turnover | 0.90 |
| Inventory Turnover | 32.15 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -19.50% in the last 52 weeks. The beta is -1.00, so Read-Gene's price volatility has been lower than the market average.
| Beta (5Y) | -1.00 |
| 52-Week Price Change | -19.50% |
| 50-Day Moving Average | 4.91 |
| 200-Day Moving Average | 5.19 |
| Relative Strength Index (RSI) | 44.24 |
| Average Volume (20 Days) | 374 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Read-Gene had revenue of PLN 12.67 million and -455,435 in losses. Loss per share was -0.04.
| Revenue | 12.67M |
| Gross Profit | 11.83M |
| Operating Income | -398,566 |
| Pretax Income | -655,406 |
| Net Income | -455,435 |
| EBITDA | 139,701 |
| EBIT | -398,566 |
| Loss Per Share | -0.04 |
Balance Sheet
The company has 5.67 million in cash and 7.52 million in debt, giving a net cash position of -1.84 million or -0.16 per share.
| Cash & Cash Equivalents | 5.67M |
| Total Debt | 7.52M |
| Net Cash | -1.84M |
| Net Cash Per Share | -0.16 |
| Equity (Book Value) | 3.60M |
| Book Value Per Share | 0.31 |
| Working Capital | 6.74M |
Cash Flow
In the last 12 months, operating cash flow was 124,279 and capital expenditures -361,925, giving a free cash flow of -237,646.
| Operating Cash Flow | 124,279 |
| Capital Expenditures | -361,925 |
| Free Cash Flow | -237,646 |
| FCF Per Share | -0.02 |
Margins
Gross margin is 93.34%, with operating and profit margins of -3.15% and -3.59%.
| Gross Margin | 93.34% |
| Operating Margin | -3.15% |
| Pretax Margin | -5.17% |
| Profit Margin | -3.59% |
| EBITDA Margin | 1.10% |
| EBIT Margin | -3.15% |
| FCF Margin | n/a |
Dividends & Yields
Read-Gene does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -0.81% |
| FCF Yield | -0.42% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Read-Gene has an Altman Z-Score of 4.49.
| Altman Z-Score | 4.49 |
| Piotroski F-Score | n/a |